Bristol-Myers Squibb CA209-627

An open label phase 2 multi-cohort trial of nivolumab in advanced or metastatic malignancies

NCT02832167

Histiocytosis, Lynch Syndrome Cancer (non-CRC), Medullary Thyroid, Merkel Cell, Abdominal Mesothelioma, Nasopharyngeal, Small cell (non-lung), Penile, Testicular, Thyroid (papillary or follicular), Thyroid (anaplastic-1st line), Uterine Sarcoma, Vulvar Cancer, Small bowel, Adrenocortical, Appendix, endocervical, adenoid-cystic like (HPV+), Cutaneous Adenocarcinoma, Schwannoma

Stage 4

Metastatic/Palliative

2nd line or later (unless no primary therapy standard)

Nivolumab

PD-1 inhibitor

Lee Schwartzberg, MD

Bristol-Myers Squibb

Phase 2

Closed to Accrual

NCT02832167

• Measurable disease required
• ECOG PS <1
• Brain mets allowed but must not be active, cannot require steroids, have at least one measurable lesion outside of brain
• Excluded tumors:
  • No Pancreatic
  • No endometrial with ER>10%
  • No ovarian
  • No breast
  • No esophageal
  • No gastric
  • No glioma
  • No hepatocellular carcinoma
  • No lymphoma (except primary CNS lymphoma)
  • No leukemia
  • No melanoma
  • No MDS
  • No lung cancer
  • No renal cell
  • No bladder
• Must not have had other cancer within 2 years
• No prior PD-1/L-1 or CTLA-4 therapy
• No autoimmune disease
• No active steroids
• No known HIV, HBV, or HCV
• See "malignancy" list for accepted tumor types

Primary- Clinical Benefit Rate: Secondary- OS, DoR, safety, pseudoprogression rates

_

_

tumor type specific

Nivolumab 240mg IV q2wk

N/A

No